Skip to content

Author

Brandon J. Manley

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study.

BACKGROUND Adjuvant pembrolizumab improves outcomes in high-risk clear cell renal cell carcinoma (ccRCC), but baseline recurrence risk varies substantially. OBJECTIVE To evaluate treatment selection, outcomes, toxicity, and risk-stratified benefit. DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort of consecu...

D. D. Shapiro, D. Roadman, V. Master et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.